HIGHLIGHTS
- who: Report and colleagues from the Internal Medicine, Northeast Georgia Medical Center, Gainesville, USA have published the research: Review began 07/10/2022 Review ended 07/17/2022 Published 07/18/2022 © Copyright, in the Journal: (JOURNAL) of July/18,/2022
- what: The authors report a case of a patient who developed myasthenia gravis crisis after receiving durvalumab.
SUMMARY
Immune checkpoint inhibitors (ICI) are new treatment therapies used for the treatment of various malignancies. Durvalumab is a Food and Drug Administration (FDA)-approved monoclonal antibody that prevents the interaction of programmed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.